Description: Sarah Cannon Research Institute (SCRI) is a global leader in oncology research, conducting clinical trials in the community for more than 30 years.
We partner with pharmaceutical and biotech companies, physicians and patients to advance the science of cancer treatments.
Sarah Cannon Research Institute (SCRI) is a global leader in oncology research, conducting clinical trials in the community for more than 30 years. In 2022, SCRI formed a joint venture with former US Oncology Research to expand clinical trial access across the country. Our contributions to pivotal research have helped to advance the majority of new cancer therapies approved by the FDA today.